anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a preparation technology and a production method of ginseng and pinellia ternate circular integrated novel formulation. The novel formulation comprises the effective element material in parts by weight: 4 parts of pinellia ternate, 4 parts of magnolia bark, 4 parts of clove, 2 parts of tangerine peel, 2 parts of ginseng and 2 parts of asarum herb. The production process comprises supersonic airflow crush, alcohol-water extraction, ultrasonic crushing extraction, water decoction and concentration, supersonic spray drying, nanogrinding, high pressure homogenization, nanoparticle preparation and the like. The novel preparation emphasizes to use the advantages of multi-collaboration, multi-target and the like embodied by the nano carrier coupling technique. After a large-scale production, the novel preparation can greatly reduce the production cost, greatly improves the product quality, and can ensure that the targeting effect and the sustained and controlled release properties of the novel formulation become stronger. The novel formulation can be taken orally or used externally, and can be taken during four time periods according to the midnight-midday ebb flow and the qi-blood flow law of human bodies. The novel preparation can also be prepared into a film agent or a transdermal agent to be applied to different parts of a human body according to the midnight-midday ebb flow and the qi-blood flow law of the human body, and can be directly absorbed through skin.
The invention relates to a thermosensitive liposome, which contains at least one phosphatidylcholine, at least one lysophospholipid, and at least one unsaturated phospholipid. The phase temperature of the liposome is 39.0DEG C-45.0DEG C. The liposome further contains a material having a long circulating characteristic and a fat-soluble active agent. Specifically, the phosphatidylcholine, the lysophospholipid, the unsaturated phospholipid, and the material having a long cycle characteristic are in a weight ratio of 69-94:1-6:1-10:4-15. And all the phospholipids and the fat-soluble active agent are in a weight ratio of 30-120:1-10. The invention also relates to a pharmaceutical composition containing the thermosensitive liposome. The invention additionally relates to application of the thermosensitive liposome and the pharmaceutical composition in preparing drugs treating tumors.
Sickle cell disease (SCD) is a genetic disorder causing painful and unpredictable Vaso-occlusive crises (VOCs) through blood vessel blockages. In this study, we propose explosive synchronization (ES) as a novel approach to comprehend the hypersensitivity and occurrence of VOCs in the SCD brain network. We hypothesized that the accumulated disruptions in the brain network induced by SCD might lead to strengthened ES and hypersensitivity. We explored ES's relationship with patient reported outcome measures (PROMs) as well as VOCs by analyzing EEG data from 25 SCD patients and 18 matched controls. SCD patients exhibited lower alpha frequency than controls. SCD patients showed correlation between frequency disassortativity (FDA), an ES condition, and three important PROMs. Furthermore, stronger FDA was observed in SCD patients with a higher frequency of VOCs and EEG recording near VOC. We also conducted computational modeling on SCD brain network to study FDA's role in network sensitivity. Our model demonstrated that a stronger FDA could be linked to increased sensitivity and frequency of VOCs. This study establishes connections between SCD pain and the universal network mechanism, ES, offering a strong theoretical foundation. This understanding will aid predicting VOCs and refining pain management for SCD patients.
JADENU can cause hepatic injury, fatal in some patients. In Study 1, 4 patients (1.3%) discontinued deferasirox because of hepatic toxicity (drug-induced hepatitis in 2 patients and increased serum transaminases in 2 additional patients). Hepatic toxicity appears to be more common in patients greater than 55 years of age. Hepatic failure was more common in patients with significant comorbidities, including liver cirrhosis and multiorgan failure [see Adverse Reactions (6.1)].

Acute liver injury and failure, including fatal outcomes, have occurred in pediatric deferasirox-treated patients. Liver failure occurred in association with acute kidney injury in pediatric patients at risk for overchelation during a volume-depleting event. Interrupt JADENU therapy when acute liver injury or acute kidney injury is suspected and during volume depletion. Monitor liver and renal function more frequently in pediatric patients who are receiving JADENU in the 14-28 mg/kg/day range and when iron burden is approaching normal. Use the minimum effective dose to achieve and maintain a low iron burden [see Dosage and Administration (2.5), Warnings and Precautions (5.6), Adverse Reactions (6.1)]. 

Measure transaminases [aspartate transaminase (AST) and alanine transaminase (ALT)] and bilirubin in all patients before the initiation of treatment and every 2 weeks during the first month and at least monthly thereafter. Consider dose modifications or interruption of treatment for severe or persistent elevations.

Avoid the use of JADENU in patients with severe (Child-Pugh C) hepatic impairment. Reduce the starting dose in patients with moderate (Child-Pugh B) hepatic impairment [see Dosage and Administration (2.4), Use in Specific Populations (8.7)]. Patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment may be at higher risk for hepatic toxicity.
A novel mammalian protein system is disclosed. This system comprises a secreted protein factor and its related membrane-bound splice variant. These novel proteins have no homology to any known protein or class or protein, yet are ubiquitously expressed in nearly all tissue types. Also disclosed are novel nucleic acids that encode the novel polypeptides of the invention. The protein system was discovered in purified populations of murine hematopoieitc stem cells. The cDNAs of the invention were cloned from a marine hematopoietic lineage negative (Lin) library.
Untreated skin was used as control. In an area of 49 cm2 (7 x 7 cm) in the infra-umbilical region CA was performed on the right side and RF on the left side. CA was administered using the beveled end of a 30G ½ needle introduced in the skin in an angle of approximately 30ºC and delivered at a velocity of 40 mL/min. The total quantity of CO2 infused was approximately 20 mL (0,3 to 0,6 mL/kg of patient's body weight) encompassing the whole delimited are. For the RF treatment, the epidermal temperature was controlled using an infrared thermometer monitored to reach 40ºC and treatment time was of five minutes starting after having reached this temperature. Sample collection varied from zero to 120 days after application. The samples were then fixed, cut in paraffin (5 µm) and stained with Picro sirus and Weigert. Morphological analyses were acquired using a Zeiss Axiophot® microscope, and they were processed using Adobe Photoshop®.
Current cancer therapies often produce an initial reduction in tumour size but may not have longterm benefits. One possible explanation for this is the presence cancer cells known as a cancer stem cells. Cancer stem cells represent a small part of the tumour but are believed to be responsible for much of the growth and spread of the cancer. They may also be more resistant to traditional types of therapy, such as chemotherapy and radiation therapy.

The purpose of this study is to test the safety and determine the optimal dose of a new experimental drug, OMP-21M18, when given in combination with FOLFIRI, a chemotherapy regimen consisting of the following three medications: folinic acid (leucovorin), 5fluorouracil and irinotecan. The administration of these three medications is a standard treatment for advanced colorectal cancer. OMP-21M18 is a humanized monoclonal antibody (a protein made in the laboratory) developed to target cancer stem cells. The way the body handles OMP21M18 will also be investigated.

Up to 32 participants, 21 years or older, will be enrolled at up to 6 centres in Australia and New Zealand. Following informed consent and screening, FOLFIRI will be administered once every 14 days (or until toxicity necessitates reducing or delaying a dose). OMP-21M18 will be administered by intravenous (IV) infusion once every 14 days on the same day as FOLFIRI. A Data Safety Monitoring Board (DSMB) will review the data for the 6 participants in each dose level after the last participant in that group has been treated for 56 days and decide whether it is safe to move up to the next highest dose level. After confirming the optimum dose, 14 additional participants will be treated at the highest dose level that the DSMB considers safe.

Participants will be assessed for disease status every 8 weeks and for safety at every visit and for 30 days after the end of study drug treatment. Safety will be assessed by adverse event monitoring, physical examination, vital signs, blood tests, cardiac monitoring, and participant interview. Response rates, duration of response, time to progression, and survival will be evaluated requiring CT or MRI scans and CEA (tumour marker) levels at baseline and then every 8 weeks. The development of antibodies to treatment will be assessed throughout the study and up to 12 weeks after the end of study drug treatment. During the study blood samples will be taken to assess whether OMP21M18 is producing desired changes to the genes and proteins related to the cancer (biomarkers). The study includes an optional part which will investigate how variations in people's genetic makeup affect their response to medications. This involves the collection of one blood sample just before participants receive their first dose of study treatment. DNA will be extracted from the blood sample for testing.
Disclosed in the present invention are a pearl-derived whitening polypeptide and a use thereof. The polypeptide is a polypeptide having an amino acid sequence according to any one of SEQ ID NOs. 1-5. The molecular docking result shows that the polypeptide has relatively strong affinity with tyrosinase, indicating that the polypeptide has a potential tyrosinase inhibition capability, so that melanin generation is inhibited. By means of cell experiments, it is further verified that the polypeptide can remarkably inhibit melanin generation of B16 melanoma cells, so that the pearl-derived polypeptide of the present invention has a potential whitening effect. Moreover, the pearl-derived polypeptide is a natural active peptide, has the advantages of good stability, weak cytotoxicity, and being easy to absorb by the human body, etc., and has large application prospects in preparation of a skin care product having a whitening effect.
The invention is related to polynucleotide-based anthrax vaccines. In particular, the invention is plasmids operably encoding Bacillus anthracis antigens, in which the naturally-occurring coding regions for the B. anthracis antigens have been modified for improved translation in human or other mammalian cells through codon optimization. In certain embodiments, the coding regions are also modified so as to remove potential N-linked glycosylation sites. B. anthracis antigens which are useful in the invention include, but are not limited to protective antigen (PA), lethal factor (LF), and fragments, variants or derivatives of either of these antigens. The invention is further directed to methods to induce an immune response to B. anthracis in a mammal, for example, a human, comprising delivering a plasmid encoding a codon-optimized B. anthracis antigen as described above. The invention is also directed to pharmaceutical compositions comprising plasmids encoding a codon-optimized B. anthracis antigen as described above, and further comprising adjuvants, excipients, or immune modulators.
Autonomic blockade will be induced by continuous intravenous infusion of trimethaphan starting at 0.5-1.0 mg/min and increasing by 1.0 mg/min every 2 to 6 minutes up to an infusion rate of 5 mg/min. Blood pressure will be restored to pre-trimethaphan levels with intravenous phenylephrine infusion at individually titrated doses, starting with 0.1 ug/kg/min. Angiotensin (1-7) will then be infused in five ascending doses ranging from 0.5 to 20 ng/kg/min. Each dose will be maintained for 10 minutes with hemodynamic measurements and blood samples collected at the end of each dosing period.
Fifty subjects (25 symptomatic and 25 asymptomatic for shoulder pain) will be recruited. All of them will be initially assessed twice with one week between the assessments. On each day, they will complete two questionnaires (DASH and SPADI) to assess pain and shoulder function. The resting length of the pectoralis minor muscle and scapular kinematics data during arm flexion will also be measured using an electromagnetic tracking system. Initially, the resting length of the pectoralis minor will be measured, and then 3 repetitions of arm elevation in the sagittal plane will be completed. The stretching protocol will be performed daily for 6 weeks. The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions. After the 6 weeks, the subject will have the same variables from the initial assessments reassessed. For the questionnaires and length of pectoralis minor a two-way ANOVA for repeated measures will be used to check the main effects of group and evaluation and whether there is interaction between them. For scapular internal/external rotation, upward/downward rotation, and tilt anterior/posterior a three-way ANOVA for repeated measures will use to analyze the main effects of group (symptomatic and asymptomatic), elevation angle of the arm (30°, 60°, 90° and 120°) and evaluation (1, 2 and 3) and whether there is evaluation x group x angle interaction. A p value less than 0.05 will be considered significant.
A stable oxidizing composition and a method of preparing such composition are presented. The composition includes a peroxygen (e.g., potassium monopersulfate, percarbonate) particle suspended in an alcoholic gel. The alcohol content in the gel prevents the peroxygen particle from coming into contact with water during storage, thereby helping maintain a high available oxygen level. When the alcoholic gel is mixed with water, it becomes less viscous and exposes the peroxygen particle to the water. The peroxygen is ready for use when it dissolves in the water. Other additives may also be suspended in the alcoholic gel for storage. The composition is prepared by first preparing an alcoholic gel, then suspending a peroxygen particle in the alcoholic gel. The alcoholic gel is prepared by combining an alcohol with a polymer.
Participants will be assigned the 'Space from Diabetes' intervention in a supported mode for 8 weeks. Participants are assigned a clinical supporter, who will be a psychological well-being practitioner in an NHS Mental Health Service. As the participant works through the programme content, the supporter will provide them with a review of their progress and interactions with the platform 6 times over the 8 week supported period.
OBJECTIVE: Vocal cord paralysis (VCP) is a serious complication in thyroidectomy operations; however, its management remains unclear. The present study evaluated the voice parameters of patients who underwent surgery using Intraoperative Neurophysiologic Monitoring (IONM).
PATIENTS AND METHODS: A total of 52 patients (41 females and 11 males) who underwent a total thyroidectomy operation were evaluated using objective and subjective voice analysis examinations before and after surgery. Acoustic parameters, such as Fundamental Frequency (F0), Shimmer, Jitter, Noise-to-Harmonic ratio (NHR), and aerodynamic parameters, including S/Z ratio and maximum phonation time (MPT), were analyzed. Objective findings, including the VHI-10 (Voice Handicap Index) and V-RQOL (Voice-Related Quality of Life), were also analyzed. The relationship between voice parameters and IONM values was investigated.
RESULTS: The objective analysis (acoustic and aerodynamic parameters) showed no difference (p>0.05). However, the subjective analysis, which involved the VHI-10 and V-RQOL measures, revealed a significant difference before and after the operation (p<0.05). The Spearman correlation analysis showed that the NHR postoperative 1st-month parameter negatively correlated (rho=-0.317, p<0.059), while the F0 postoperative 6th-month parameter positively correlated (rho=0.347) with the amplitude difference before and after dissection (Right R2-R1 difference) for the right RLN measured in IONM.
CONCLUSIONS: Patients who are planning to undergo a thyroidectomy procedure should undergo voice assessment during both the preoperative and postoperative periods. IONM could improve voice quality outcomes.
The invention relates to the field of health drink, in particular to health tea capable of preventing breast cancer. The health tea is prepared from raw materials in parts by weight as follows: 25-35 parts of ganoderma lucidum, 25-35 parts of myrica rubra kernel oil, 35-45 parts of Chinese actinidia roots, 25-35 parts of salvia miltiorrhiza, 15-25 parts of tangerine seeds, 25-35 parts of poria cocos, 150-200 parts of black fungi, 60-80 parts of kudzuvine roots, 50-80 parts of siraitia grosvenorii and 1,800-2,200 parts of water. The invention further relates to a preparation method of the health tea capable of preventing the breast cancer. The method comprises steps of material taking, material separation, decoction and mixing. The invention aims to provide the health tea capable of preventing the breast cancer and the preparation method of the health tea. By means of a reasonable matching and preparation process, the whole health tea is neutral by utilizing drug properties of the raw materials, besides, the drug properties of the raw materials can be exerted, better breast cancer treatment and prevention effects are realized through matching, and meanwhile, the health tea keeps certain sweetness and is suitable for drinking.
Prenatal per and polyfluoroalkyl substances (PFAS) exposure is associated with adverse birth outcomes. There is an absence of evidence on the relationship between maternal and paternal preconception PFAS exposure and birth outcomes. This study included 312 mothers and 145 fathers with a singleton live birth from a preconception cohort of subfertile couples seeking fertility treatment at a U.S. clinic. PFAS were quantified in serum samples collected before conception. Gestational age (GA) and birthweight (BW) were abstracted from delivery records. We also assessed low birthweight (BW < 2500 g) and preterm birth (GA < 37 completed weeks). We utilized multivariable linear regression, logistic regression, and quantile-based g computation to examine maternal or paternal serum concentrations of individual PFAS and mixture with birth outcomes. Maternal serum concentrations of perfluorooctanesulfonate (PFOS), perfluorohexanesulfonate (PFHxS), and the total PFAS mixture were inversely associated with birthweight. Maternal PFOS concentration was associated with a higher risk of low birthweight. Conversely, paternal PFOS and PFHxS concentrations were imprecisely associated with higher birthweight. No associations were found for gestational age or preterm birth. The findings have important implications for preconception care. Future research with larger sample sizes would assist in validating these findings.
PURPOSE:To obtain a hair fixing agent composition excellent in hair fixing performance, capable of facilitating styling, free from sticky feeling, giving excellent feeling and having excellent finishing and style-keeping ability. CONSTITUTION:This hair fixing agent composition contains (A) 0.1-10wt.%, especially, 1-6wt.% of a water-dispersible polyester resin. (B) 0.01-10wt.%, especially, 0.1-3wt.% of thickener, preferably, a polysaccharide polymer or a polyvinyl alcohol and (C) water. In this composition, the weight ratio of the component A to the component B (A/B) is preferably 0.1-100, especially, 0.1-25. As for the component A, a polymer obtained by polycondensing a dicarboxylic acid with a diol and a bifunctional monomer having >=1 of sulfonic acid group on an aromatic ring beside the functional groups, especially a polymer obtained by the polycondensation of isophthalic acid, ethylene glycol, cyclohexane- diethanol and sulfoisophthalic acid, is preferable. Styling performance is improved by adjusting the viscosity at 25 deg.C of a final product or an aerosol stock solution to >=20cP, especially, >=100cP.
In clinical practice blood gas analysis is an essential tool for monitoring respiratory status. The gold-standard method is arterial blood gas analysis (ABG) of blood from the patient's radial or femoral artery. An alternative to arterial sampling commonly used is arterialized capillary blood gas analysis from the earlobe (CBGE). Though CBGE is less invasive and can be performed by non-medical staff, it is less useful in the acute setting because an adequate vasodilatation is needed which typically lasts for at least 10 minutes and the quality of results tends to be operator dependable. Different trials have evaluated the agreement between ABG and CBGE. Whereas a close agreement between ABG and CBGE has been found for evaluating pH and the partial pressure of carbon dioxide (PCO2), several trials showed considerable variations for the partial pressure of oxygen (PO2) and that CBGE tends to underestimate PO2. Similar findings apply for capillary blood gas analysis from the fingertip (CBGF) which is even less accurate compared to CBGE in estimating PO2. Recently a method has been developed to calculate ABG values mathematically from peripheral venous blood, supplemented with oxygen saturation (SpO2) measurement by pulse oximetry, by use of venous-to-arterial conversion (v-TAC) software (OBI Medical, Denmark). The principle of the method is a mathematical transformation of venous blood gas analysis (VBG) values to arterialised values (aVBG) by simulating the transport of blood back through the tissue (6). This approach leads to a clinically acceptable agreement between ABG and aVBG for pH and PCO2. For PO2 the limits of agreement of aVBG are similar to those of PO2 from CBGE for values below 75 mmHg and with mean bias close to zero. However, it has not been evaluated previously whether v-TAC software can be used to calculate ABG values from CBGE (aCBGE) or CBGF (aCBGF). As CBGE and CBGF values are much closer to ABG values, compared to VBG values, the agreement between aCBGE/aCBGF and ABG in terms of pH, PCO2 and pO2 might be better compared to CBG without mathematical arterialisation by v-TAC.